Real-world study for CalliSpheres-loaded microsphere embolization in the treatment of unresectable advanced non-small-cell carcinoma

Prospective study of the efficacy and safety of intra-arterial infusion of cisplatin combined with 5-fluorouracil and the use of CalliSpheres-loaded microspheres loaded with epirubicin embolization for the treatment of non-surgical advanced non-small-cell carcinoma

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800017984

Enrollment

Unknown

Registered

2018-08-25

Start date

2018-09-01

Completion date

Unknown

Last updated

2018-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small-cell carcinoma

Interventions

Case series:Arterial infusion of cisplatin and 5-fluorouracil combined with CalliSpheres-loaded microspheres loading with epirubicin for embolization

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Aged =18 years old; (2) Pathological and/or cytological examination confirmed by fiberoptic bronchoscopy or CT-guided biopsy as NSCLC, international lung cancer stage III, IV, genetic testing (EGFR, ALK gene test) negative or rejected / no economic ability to use targeted drugs , interventional therapy as the main treatment; (3) Life expectancy is expected to exceed 3 months; (4) Eastern Cooperative Oncology Group(ECOG) performance status=2; (5) Pregnancy tests for women of reproductive age must be negative; both men and women should agree to use effective contraception during treatment and within the next year; (6) Subjects with good compliance and followed up voluntarily participated in this study and signed informed consent.

Exclusion criteria

Exclusion criteria: (1) Surgical tumor resection or local ablation (2) INR > 1.5, or underway anticoagulation therapy or known hemorrhagic diseases; (3) unstable coronary heart disease or recent myocardial infarction (within one year); (4) Recent infections required antibiotic treatment; (5) The patient is accompanied by other primary tumors; (6) The DSA showed that the tumor blood supply artery contained the anterior spinal artery; the artery was too thin and the intubation was unsuccessful; (7) The comorbidity or social environment that may cause the subject to fail to follow the study plan or even jeopardize patient safety.

Design outcomes

Primary

Measure	Time frame
overall response rate;disease control rate;	—

Secondary

Measure	Time frame
Quality of life improvement rate;Clinical symptom improvement rate;Rate of tumor resection in descending stage;	—

Countries

China

Contacts

Public ContactWu Gang

The First Affiliated Hospital of Zhengzhou University

wuganghenan2004@163.com+86 13938570175

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026